|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM356951553 |
| 003 |
DE-627 |
| 005 |
20231226071538.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202303542
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1189.xml
|
| 035 |
|
|
|a (DE-627)NLM356951553
|
| 035 |
|
|
|a (NLM)37192546
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dai, Xiaomeng
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Induction of Tumor Ferroptosis-Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 01.09.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The combination of ferroptosis inducers and immune checkpoint blockade can enhance antitumor effects. However, the efficacy in tumors with low immunogenicity requires further investigation. In this work, a water-in-oil Pickering emulsion gel is developed to deliver (1S, 3R)-RSL-3 (RSL-3), a ferroptosis inducer dissolved in iodized oil, and programmed death-1 (PD-1) antibody, the most commonly used immune checkpoint inhibitor dissolved in water, with optimal characteristics (RSL-3 + PD-1gel). Tumor lipase degrades the continuous oil phase, which results in the slow release of RSL-3 and PD-1 antibody and a notable antitumor effect against low-immunogenic hepatocellular carcinoma and pancreatic cancer. Intriguingly, the RSL-3 + PD-1@gel induces ferroptosis of tumor cells, resulting in antitumor immune response via accumulation of helper T lymphocyte cells and cytotoxic T cells. Additionally, the single-cell sequence profiling analysis during tumor treatment reveals the induction of ferroptosis in tumor cells together with strong antitumor immune response in ascites
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a ferroptosis
|
| 650 |
|
4 |
|a immune checkpoint blockade
|
| 700 |
1 |
|
|a Zhang, Jia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bao, Xuanwen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Yixuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jin, Yuzhi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Chenjing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Hangyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Lulu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ye, Chanqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Chuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Chun-Xia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sheng, Jianpeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ren, En
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Hongjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Weijia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Baiheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruan, Jian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Zhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Dong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Peng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 35 vom: 17. Sept., Seite e2303542
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:35
|g day:17
|g month:09
|g pages:e2303542
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202303542
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 35
|b 17
|c 09
|h e2303542
|